Member Info for amones

US approval for Surufatinib should change the picture.

105th position among the top UK companies ! That’s excellent news to know, Davey. Thanks for searching this. Does our CEO and his colleagues at HCM management aware of their ranking position?
It is high time for HCM to get listed on the main market. No more delay please, Mr Hogg.
As Davey has correctly mentioned, it will be a sought after stock by the fund managers not just here but also by investors in China and (?HK).

Totally agree Jatw. I came across similar situation twice, few years ago, when two stocks in my portfolio were delisted from LSE and migrated to NYSE. My stockbroker wasn’t dealing with foreign listed companies and hence, ‘recommended’ an European broker instead. Similar situation could happen if HCM moves out completely from LSE. Best option would be for the company to move out of AIM market and get listed on the main LSE market. It will be good for the UK investors and at the same time, can attract investors from China (?and HK) to invest in LSE listed HCM shares using the London-Shanghai link. I wonder why the financial analysts don’t ask the CEO about this during the so called ‘discussion sessions’.

If the ‘London-Shanghai stock markets link’ works out well, it shall not only helps to get an uplift in sp but also the much needed funding, without having to list at HK.
(It might not be as simple as this, but few other posters had mentioned these benefits on this discussion forum, months ago)

Nice to read your posts after brief hiatus, Davey.
Although your opinion is fair enough about HCM moving to the main LSE market, couple of benefits that have been discussed here in the recent past;
1. fund managers who are not able invest in AIM listed companies, can add HCM on their wish list. That might boost the sp significantly.
2. ‘London-Shanghai stock link’ - allows private and institutional investors based in China and HK to invest in LSE listed HCM. (again, AIM listed stocks excluded at present). That can bring in significant interest.
These two reasons should be good enough for the company to try.

I keep repeating this. Is the company making any efforts to move out of AIM and get listed on main market of LSE? Pharma companies are generally doing well and the same could be expected of HCM. Its deep pipeline and its efficient management will be enough to get the attention of bigger funds.
Why the delay ?

Another good post, Jatw. Thanks.
To my query of low market valuation despite a deep pipeline, you seem to think ‘not owning a first line therapy’ could be one of the reasons. Would Surufatinib be able to fill that void to a little extent? As per information provided yesterday by the company in relation to the second NDA acceptance by the authorities, it is mentioned ‘there is no effective therapy’ in China for advanced Pancreatic NET. It also says ...’In the U.S., the Food and Drug Administration (“FDA”) granted Fast Track Designation status to surufatinib for both the non-pancreatic NET and pancreatic NET development programs in April 2020.  Chi-Med has initiated preparatory work for the U.S. NDA and intends to utilize a rolling submission, which is expected to start in late 2020.  In addition, the Marketing Authorization Application (“MAA”) submission in Europe is planned for 2021’
We can, at least, keep our fingers crossed! Of course, we are following a faster tortoise and not a hare!!

Btw, on stockwit site, yesterday’s post- market sp of ADRs has gone up by $1.74 or 5% raise! I doubt if it is accurate.

Forgot to add, ..as a holder of 10 odd years, I keep asking these questions and continue to hold my shares.:)

Sensible write up, Jatw. Thanks.
Is the present market valuation (£3.6 billion) for a pharmaceutical research company with a pipeline of this nature, a separate commercial arm and partly owned by CKHH, realistically closer to the true value?
What could be the individual valuations of drugs ready to be launched, drugs waiting for final approval and drug candidates in different stages of clinical trials? Is there another company of similar size and with similar pipeline for comparison purposes?

AW, sixty quids from five??
Are you not over optimistic??
However, I don’t want to comment if such valuation is possible or not.
I have experienced the thrill when the ‘‘old/undiluted‘ hcm shares climbing from £10 to £59 (end of 2017) and in the same breath, I want to add the stomach wrenching experience of grand falls too!

If you have any numbers, like valuation of individual therapeutic candidate in the pipeline would be helpful in envisaging the future.

Its nearly 2 weeks since Davey’s last post on this board. His well researched posts have always been source of useful information to readers of this board. Hopefully all is well and he continues to update us about this excellent company.

Interesting to see number of buys in the afternoon sessions. Perhaps, trading of AIM listed HCM shares depends on the trading of ADRs on NYSE.

Another feather in the cap?
New therapeutic candidate from Chi-Med‘s pipeline for phase 2 trial in advanced liver Cancer. Let’s hope it will be successful in helping the patients.

Enjoyable indeed! Good buying pressure of ADRs helping to keep up the momentum. I don’t remember the SP had ever managed to maintain such healthy position for 3-4 weeks at a stretch, like this time. There must few good reasons for this.

Davey/JatW, do you know any stocks related discussion forum, similar to lse, for HK listed companies? Thanks

No, No Sorry Davey, I wasn’t commenting on your post.
It was about the message by Tickeron, ?a Bot.

‘Cheerleader’ would be a suitable new title!!

Davey,
Once in a while, I check messages where mr bucket posts as the cheerleader. The latest message, presumably by a bearish bot, is quoting some matrices and imaginary calculations, appears bit negative. What is it trying to advise day traders, to sell? I am sure mrbucket will carry on doing what he is good at.

All of these have met the precondition of proven record of commercialisation successes

Thanks Jatw. Seond, third and many more private equity houses investing in HCM would be fantastic news to this share.
A number of times, we have read here about the advantages of moving out of AIM and listing on the main stock market of LSE. One such advantage being, private fund managers who, at present, are not allowed to invest in AIM listed shares will be able to add HCM into their fund portfolios. Even a handful of such investments would be helpful to maintain a healthy sp.
Why a world class pharma company is still listed on AIM? We should keep asking the directors. They might consider to move.

Would that article be the remote reason behind the rapid pace of today’s free fall??